ManageChatDiscover
351489

Safety and Mortality: Monitoring the Patients on Rivaroxaban

Article

Last updated: 05 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

No enough information available in matter of 
patient on Rivaroxaban a direct factor Xa 
inhibitor specially in Saudi population. In 
addition, patient with chronic kidney disease, 
valvular atrial fibrillation or liver disease must 
not be considered for such therapeutic change. 

DOI

10.21608/cvrepj.2022.351489

Volume

6

Article Issue

2

Related Issue

47293

Issue Date

2022-12-01

Receive Date

2024-04-23

Publish Date

2022-12-01

Print ISSN

2636-4204

Online ISSN

2636-4212

Article File

CVREPJ3514891669845600.pdf

PDF . 98.6kB

Link

https://cvrepj.journals.ekb.eg/article_351489.html

Detail API

https://cvrepj.journals.ekb.eg/service?article_code=351489

Order

351,489

Type

Abstracts

Type Code

3,139

Publication Type

Journal

Publication Title

Cardiovascular Research Prove Journal

Publication Link

https://cvrepj.journals.ekb.eg/

MainTitle

Safety and Mortality: Monitoring the Patients on Rivaroxaban

Details

Type

Article

Created At

20 Dec 2024